EP1181050A1 - Methodes pouvant empecher la reactivation d'un virus latent et controler sa replication - Google Patents

Methodes pouvant empecher la reactivation d'un virus latent et controler sa replication

Info

Publication number
EP1181050A1
EP1181050A1 EP00928658A EP00928658A EP1181050A1 EP 1181050 A1 EP1181050 A1 EP 1181050A1 EP 00928658 A EP00928658 A EP 00928658A EP 00928658 A EP00928658 A EP 00928658A EP 1181050 A1 EP1181050 A1 EP 1181050A1
Authority
EP
European Patent Office
Prior art keywords
cell
virus
composition
specifically binds
subsequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00928658A
Other languages
German (de)
English (en)
Other versions
EP1181050A4 (fr
Inventor
Sally R. Sarawar
Stephen Philip Schoenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Institute for Allergy and Immunology
Original Assignee
La Jolla Institute for Allergy and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Institute for Allergy and Immunology filed Critical La Jolla Institute for Allergy and Immunology
Priority to EP08021371A priority Critical patent/EP2039368A3/fr
Publication of EP1181050A1 publication Critical patent/EP1181050A1/fr
Publication of EP1181050A4 publication Critical patent/EP1181050A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • PCR can be used to measure the amount of viral nucleic acid or viral message in an individual before and after practicing the methods of the invention to assess the relative levels of latent, versus active, virus.
  • antibody refers to a peptide or polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an epitope, such as, e.g., a CD40 polypeptide epitope. See, e.g. Fundamental Immunology, Third Edition, W.E. Paul, ed., Raven Press, N.Y. (1993); Wilson (1994) J. Immunol. Methods 175:267-73; Yarmush (1992) J. Biochem. Biophys.
  • composition refers to a composition suitable for pharmaceutical use in a subject.
  • the pharmaceutical compositions of this invention are formulations that comprise a pharmacologically effective amount of a composition comprising, e.g., a CD40 ligand, or an anti-CD40 antibody, and a pharmaceutically acceptable carrier.
  • Recombinant means also encompass the ligation of nucleic acids having various coding regions or domains or promoter sequences from different sources into an expression cassette or vector for expression of, e.g., inducible or constitutive expression of polypeptide coding sequences in the vectors used to practice this invention.
  • one exemplary guideline to select conservative substitutions includes (original residue followed by exemplary substitution): ala/gly or ser; arg/ lys; asn/ gin or his; asp/glu; cys/ser; gln/asn; gly/asp; gly/ala or pro; his/asn or gin; ile/leu or val; leu/ile or val; lys/arg or gin or glu; met/leu or tyr or ile; phe/met or leu or tyr; ser/thr; thr/ser; frp/tyr; tyr/frp or phe; val/ile or leu.
  • peptides can be isolated from natural sources (e.g., as fragments of isolated CD40 polypeptides), or can be synthetically or recombinantly generated polypeptides, as described above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes pouvant empêcher la réactivation d'un virus latent et contrôler sa réplication chez un individu. L'invention concerne également une méthode pouvant moduler la fonction des lymphocytes T à CD4 par administration d'anticorps aux CD-40. Une telle modulation permet le remplacement ou la supplémentation de la fonction des lymphocytes T à CD4, notamment pour mieux traiter la maladie infectieuse.
EP00928658A 1999-04-30 2000-04-28 Methodes pouvant empecher la reactivation d'un virus latent et controler sa replication Withdrawn EP1181050A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08021371A EP2039368A3 (fr) 1999-04-30 2000-04-28 Procédé pour empêcher la réactivation d'un virus latent et contrôler la réplication du virus

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13173099P 1999-04-30 1999-04-30
US131730P 1999-04-30
PCT/US2000/011734 WO2000066155A1 (fr) 1999-04-30 2000-04-28 Methodes pouvant empecher la reactivation d'un virus latent et controler sa replication

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP08021371A Division EP2039368A3 (fr) 1999-04-30 2000-04-28 Procédé pour empêcher la réactivation d'un virus latent et contrôler la réplication du virus

Publications (2)

Publication Number Publication Date
EP1181050A1 true EP1181050A1 (fr) 2002-02-27
EP1181050A4 EP1181050A4 (fr) 2005-05-18

Family

ID=22450762

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00928658A Withdrawn EP1181050A4 (fr) 1999-04-30 2000-04-28 Methodes pouvant empecher la reactivation d'un virus latent et controler sa replication
EP08021371A Withdrawn EP2039368A3 (fr) 1999-04-30 2000-04-28 Procédé pour empêcher la réactivation d'un virus latent et contrôler la réplication du virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08021371A Withdrawn EP2039368A3 (fr) 1999-04-30 2000-04-28 Procédé pour empêcher la réactivation d'un virus latent et contrôler la réplication du virus

Country Status (4)

Country Link
EP (2) EP1181050A4 (fr)
JP (1) JP3581660B2 (fr)
AU (1) AU4685900A (fr)
WO (1) WO2000066155A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10059642C2 (de) 2000-12-01 2003-02-27 Bbt Bergedorfer Biotech Gmbh Reinigungsmittel
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2004063363A1 (fr) * 2003-01-16 2004-07-29 Kansai Technology Licensing Organization Co. Ltd. Sous ensembles de cellules dendritiques differentes
WO2007054658A1 (fr) * 2005-11-14 2007-05-18 King's College London Contrôle de réponses immunitaires

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5192537A (en) 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5646046A (en) 1989-12-01 1997-07-08 Akzo Nobel N.V. Method and instrument for automatically performing analysis relating to thrombosis and hemostasis
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
TW304957B (fr) 1991-06-18 1997-05-11 Lilly Co Eli
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5738852A (en) 1993-04-20 1998-04-14 Solis Therapeutics, Inc. Methods of enhancing antigen-specific T cell responses
JP3675819B2 (ja) 1993-10-01 2005-07-27 イミュネックス・コーポレーション Ｃｄ４０に対する抗体
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
DE69535002T2 (de) 1994-03-08 2006-12-07 Memorial Sloan-Kettering Cancer Center Rekombinante humanisierte antikörper gegen fb5
DE4411266C2 (de) 1994-03-31 2001-05-17 Danfoss As Analyseverfahren und Analysevorrichtung
MX9605088A (es) 1994-04-28 1997-08-30 Boehringer Ingelheim Pharma Metodos para proliferar y diferenciar celulas b y sus usos.
US5587309A (en) 1994-04-29 1996-12-24 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo
CA2195557C (fr) 1994-08-12 2006-10-17 Shui-On Leung Immunoconjugues et anticorps de type humain specifiques contre des lymphomes malins a cellules b et des cellules leucemiques
US6045671A (en) 1994-10-18 2000-04-04 Symyx Technologies, Inc. Systems and methods for the combinatorial synthesis of novel materials
US5665350A (en) 1994-11-23 1997-09-09 University Of Massachusetts Medical Center Cell cycle dependent transplantation and ex vivo gene therapy
US5770201A (en) 1994-12-23 1998-06-23 Rijsuniversiteit Te Leiden HA-2 antigenic peptide
GB9500851D0 (en) 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
US5721354A (en) 1995-03-31 1998-02-24 Aviron Human cytomegalovirus DNA sequences
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
DK0892643T4 (da) 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
US5942443A (en) 1996-06-28 1999-08-24 Caliper Technologies Corporation High throughput screening assay systems in microscale fluidic devices
US5792431A (en) 1996-05-30 1998-08-11 Smithkline Beecham Corporation Multi-reactor synthesizer and method for combinatorial chemistry
US6017527A (en) 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US5780431A (en) 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6054047A (en) 1998-03-27 2000-04-25 Synsorb Biotech, Inc. Apparatus for screening compound libraries
US6027488A (en) 1998-06-03 2000-02-22 Genetronics, Inc. Flow-through electroporation system for ex vivo gene therapy

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AWAN A.R. ET AL: 'COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY PREPARATIONS FOR THE TOPICAL TREATMENT OF HERPES SIMPLEX VIRUS ASSESSED USING A MURINE ZOSTERIFORM INFECTION MODEL' ANTIVIRAL CHEMISTRY & CHEMOTHERAPY vol. 9, no. 1, January 1998, LONDON, GB, pages 19 - 24, XP009029082 *
DATABASE AIDSLINE [Online] 5TH CONF RETROVIR OPPOR INFECT, P. 86, ABS. # 37, 1998 DI MARZIO ET AL: 'GM-CSF or CD40L suppresses chemokine receptor expression and HIV-1 entry into human monocytes and macrophages', XP002102579 Retrieved from STN, accession no. 1998:7519 AIDSLINE Database accession no. AIDS-98928965 *
FUNAKOSHI S. ET AL: 'Inhibition of human B-cell lymphoma growth by CD40 stimulation.' BLOOD vol. 83, no. 10, 15 May 1994, PHILADELPHIA, VA, US, pages 2787 - 2794, XP002919673 *
JOURNAL ARTICLE CELL STRUCTURE AND FUNCTION vol. 19, no. 6, 30 September 1994, JAPAN SOCIETY FOR CELL BIOLOGY (JSCB), KYOTO, JP, page 510, XP008062290 *
MURPHY W.J. ET AL: 'Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes' BLOOD vol. 86, no. 5, 01 September 1995, AMERICAN SOCIETY OF HEMATOLOGY, US, pages 1946 - 1953, XP002961507 *
No further relevant documents disclosed *
See also references of WO0066155A1 *
SIN J.I. ET AL: 'Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo.' HUMAN GENE THERAPY vol. 12, 10 June 2001, UNITED STATES, pages 1091 - 1102 *
TOKA F.N. ET AL: 'Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation' VIROLOGY vol. 331, 2005, pages 151 - 158 *
WILLIAMS MATTHEW A. ET AL: 'Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen.' JOURNAL OF IMMUNOLOGY vol. 169, 15 November 2002, BALTIMORE, US, pages 5387 - 5391 *

Also Published As

Publication number Publication date
JP2002543150A (ja) 2002-12-17
EP2039368A2 (fr) 2009-03-25
JP3581660B2 (ja) 2004-10-27
EP1181050A4 (fr) 2005-05-18
AU4685900A (en) 2000-11-17
WO2000066155A1 (fr) 2000-11-09
EP2039368A3 (fr) 2009-04-01

Similar Documents

Publication Publication Date Title
DK1704166T3 (en) M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
ES2428089T3 (es) Usos de anticuerpos anti-cd40
RU2542394C2 (ru) Гуманизированные антитела против light и их применение
CZ20012465A3 (cs) Způsob inhibice aktivity ztnf4, izolovaná molekula polynukleotidu, expresní vektor, kultivovaná buňka, způsob přípravy polypeptidu a izolovaný polypeptid
RU2769352C2 (ru) Антитела и полипептиды, направленные против cd127
EP1572881A2 (fr) Polypeptides taci et br3 et leurs utilisations
CA2396793A1 (fr) Utilisation d'agonistes ou d'antagonistes pour moduler l'activite de molecules associees au tnf
WO2001012812A2 (fr) Recepteur de baff (bcma) et agent immunoregulateur
MXPA01007464A (es) Baff, inhibidores del mismo y su uso en la modulacion de la respuesta de celula b.
CA2469230A1 (fr) Anticorps inhibiteurs de gdf-8 et utilisations associees
EP1833848A2 (fr) Nouveau domaine de regulation du recepteur tnf
JP6193275B2 (ja) Ｂ細胞媒介炎症性疾患を治療するための方法
US20030215450A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
JP2010229156A (ja) 早期活性化分子のターゲティングに基づく免疫調節
EP1458411A2 (fr) Anticorps monoclonaux ligands anti-rank convenant au traitement de troubles lies aux ligands de rank
DK2340039T3 (en) Use of IL-20 antagonists for treating osteoporosis
JP2007308465A (ja) 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
EP2039368A2 (fr) Procédé pour empêcher la réactivation d'un virus latent et contrôler la réplication du virus
JP2010155843A (ja) 骨発生の調節方法
KR20230096959A (ko) Il-10을 포함하는 이중 시토카인 융합 단백질
US20040213788A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2007201279B2 (en) Ligand for herpes simplex virus entry mediator and methods of use
CA2505852A1 (fr) Traitement de troubles immunologiques renaux par des inhibiteurs de la voie de la lymphotoxine
AU2002322616A1 (en) Tacis and BR3 polypeptides and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050405

17Q First examination report despatched

Effective date: 20060410

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20081210